(Q89217839)

English

Systemic sclerosis

scientific article published on 23 April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1 reference

Europe PubMed Central

Systemic sclerosis (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

author name string

Yannick Allanore

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Robert Simms

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Oliver Distler

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Maria Trojanowska

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Christopher P Denton

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

John Varga

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

publication date

23 April 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Nature Reviews Disease Primers

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

15002

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Prediction of pulmonary complications and long-term survival in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Autoantibodies in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy, and environmental triggers

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Systemic sclerosis at the crossroad of polyautoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

The pathogenesis of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Cellular and molecular aspects of vascular dysfunction in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Immunochip analysis identifies multiple susceptibility loci for systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Systemic sclerosis and lupus: points in an interferon-mediated continuum

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Increased serum levels of soluble CD163 in patients with scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

T cells in systemic sclerosis: a reappraisal

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Role of interleukin-13 in fibrosis, particularly systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Stimulatory Autoantibodies to the PDGF Receptor in Systemic Sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Recent developments in myofibroblast biology: paradigms for connective tissue remodeling

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Fibrosis--a lethal component of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Transforming growth factor beta as a therapeutic target in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Focal adhesion kinase links mechanical force to skin fibrosis via inflammatory signaling.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Role of PDGF in fibrotic diseases and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Wnt coreceptor Lrp5 is a driver of idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Connective tissue diseases: systemic sclerosis: beyond limited and diffuse subsets?

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Epigenetics, the holy grail in the pathogenesis of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

The role of genetics and epigenetics in the pathogenesis of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

DNA hypermethylation of the forkhead box protein 3 (FOXP3) promoter in CD4+ T cells of patients with systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Trichostatin A blocks TGF-beta-induced collagen gene expression in skin fibroblasts: involvement of Sp1.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

MicroRNA-21 in scleroderma fibrosis and its function in TGF-β-regulated fibrosis-related genes expression

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

MicroRNA-29, a key regulator of collagen expression in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Cigarette smoking is not a risk factor for systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Survival in scleroderma: results from the population-based South Australian Register

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Environmental risk factors in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Epstein-Barr virus infection induces aberrant TLR activation pathway and fibroblast-myofibroblast conversion in scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

2013 American College of Rheumatology/European League against rheumatism classification criteria for systemic sclerosis outperform the 1980 criteria: data from the Canadian Scleroderma Research Group

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Performance of the new ACR/EULAR classification criteria for systemic sclerosis in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic scl

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Early Systemic Sclerosis: Analysis of the Disease Course in Patients With Marker Autoantibody and/or Capillaroscopic Positivity

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Severe organ involvement in systemic sclerosis with diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Pulmonary hypertension in rheumatic diseases: epidemiology and pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the In

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American Co

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Screening for interstitial lung disease in systemic sclerosis: performance of high-resolution CT with limited number of slices: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Interstitial lung disease in systemic sclerosis: a simple staging system

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Predictive role of capillaroscopic skin ulcer risk index in systemic sclerosis: a multicentre validation study

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

My approach to the treatment of scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Systemic sclerosis-associated pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Macitentan and morbidity and mortality in pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Combination therapy in the management of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Diagnosis, management and prevention of scleroderma renal disease

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Scleroderma renal crisis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Scleroderma renal crisis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Scleroderma renal crisis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), Physician- and Patient-Rated Global Assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical T

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Therapeutic options for digital ulcers in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Gastrointestinal manifestations of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Severe gastrointestinal involvement in systemic sclerosis: report of five cases and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Gastric antral vascular ectasia (watermelon stomach) in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Tumoral calcinosis in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Calcinosis cutis in autoimmune connective tissue diseases

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Validation of a novel radiographic scoring system for calcinosis affecting the hands of patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Determinants of morbidity and mortality of systemic sclerosis in Canada

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Health-related quality of life in systemic sclerosis: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Measuring Pain in Systemic Sclerosis: Comparison of the Short-form McGill Pain Questionnaire Versus a Single-item Measure of Pain

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Clinical correlates of sleep problems in systemic sclerosis: the prominent role of pain.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Disability in systemic sclerosis -- a longitudinal observational study

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Association of pruritus with quality of life and disability in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Work Disability in Systemic Sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Work disability in scleroderma is greater than in rheumatoid arthritis and is predicted by high HAQ scores.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Validation of the UCLA Scleroderma Clinica Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Association of the autoimmune disease scleroderma with an immunologic response to cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Psychosocial aspects of systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Psychological health and well-being in systemic sclerosis: State of the science and consensus research agenda.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Prevalence of current, 12-month and lifetime major depressive disorder among patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Major depression diagnoses among patients with systemic sclerosis: baseline and one-month followup.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Development and validation of the brief-satisfaction with appearance scale for systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Derivation and validation of a prediction rule for two-year mortality in early diffuse cutaneous systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Interstitial lung disease in connective tissue disease--mechanisms and management

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Animal models of systemic sclerosis: prospects and limitations

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Treatment of diffuse systemic sclerosis with hyperimmune caprine serum (AIMSPRO): a phase II double-blind placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Changes in causes of death in systemic sclerosis, 1972-2002

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Targeted therapies for systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Fli1 represses transcription of the human α2(I) collagen gene by recruitment of the HDAC1/p300 complex

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Chromatin immunoprecipitation on microarray analysis of Smad2/3 binding sites reveals roles of ETS1 and TFAP2A in transforming growth factor beta signaling.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

The induction of CCN2 by TGFbeta1 involves Ets-1.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

The Role of TGF-β Receptors in Fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Egr-1: new conductor for the tissue repair orchestra directs harmony (regeneration) or cacophony (fibrosis).

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Integrin β1: A Mechanosignaling Sensor Essential for Connective Tissue Deposition by Fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

CCN2 is required for the TGF-β induced activation of Smad1-Erk1/2 signaling network

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

From tissue mechanics to transcription factors

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

STAT4is a genetic risk factor for systemic sclerosis having additive effects withIRF5on disease susceptibility and related pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

BANK1is a genetic risk factor for diffuse cutaneous systemic sclerosis and has additive effects withIRF5andSTAT4

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Genome-wide scan identifies TNIP1, PSORS1C1, and RHOB as novel risk loci for systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Brief Report: Candidate gene study in systemic sclerosis identifies a rare and functional variant of the TNFAIP3 locus as a risk factor for polyautoimmunity

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

New insight on the Xq28 association with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Evidence of the contribution of the X chromosome to systemic sclerosis susceptibility: association with the functional IRAK1 196Phe/532Ser haplotype.

1 reference

https://api.crossref.org/works/10.1038%2FNRDP.2015.2

31 March 2020

Identifiers

10.1038/NRDP.2015.2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27189141%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q89217839&oldid=1386111804"